Abstract:Assuring transfusion safety is an essential element of health care in all countries, requiring government commitment, national policy and a legal framework. Fundamental safety strategies include selection of low risk donors, Good Manufacturing Practices in preparation of blood components, and appropriate clinical use including avoidance of unnecessary transfusions. Hemovigilance, including surveillance for known adverse events and sentinel reporting of unexpected adverse events, enhances safety through benchmarking to promote best practices and by enabling rapid responses to new threats. Preventing transmission of infectious diseases is a principal safety concern. Selection of low risk donors includes use of screening questions to elicit risk factors known to be associated with transmissible infections. Laboratory testing for specific infectious disease markers is an established strategy for interdicting contaminated donations. The sensitivity, specificity, and operational convenience of laboratory testing have improved over time and newer technologies are imminent. Donor screening and laboratory testing, while highly effective in reducing risk, cannot eliminate all risk from known agents and must be developed de novo to address emerging infections. In contrast, pathogen reduction technologies offer the possibility for robust inactivation of a broad spectrum of blood transmissible agents and provide an added safeguard against newly emerging infectious threats of most types. Current pathogen reduction methods also inactivate leukocytes, adding safety benefits similar to leukocyte removal and product irradiation. However, to date, concerns about the safety and efficacy of cellular blood components treated by pathogen reduction have prevented approval of these technologies in the U.S. and Canada. FDA is promoting clinical and basic scientific studies to clarify these issues and would consider alternative approaches to assuring blood safety if pathogen reduction technologies are proven to be safe and effective.

Constitutionality of exemption laws on guarantee of purity for blood transfusions and tissue and organ transplants.

Jehovah's witnesses, blood transfusions and transplantations

Quality Assessment of Established and Emerging Blood Components for Transfusion

A Comprehensive Analysis of Litigation in Organ Transplantation for Allegations of Insufficient Policy Coverage, Discrimination and Malpractice

Alternative strategies in assuring blood safety: An Overview

Ravelment of Law and Medicine——An Issue Concerning Eevidence Rrecognition from a Case of Hepatitis C Caused by Blood Filtering Transfusion

Proceedings of a consensus conference: blood-borne HIV and hepatitis-optimizing the donor selection process

[Importance of the determination of immunocomplexes in glomerulonephritis].

Ethical Issues Related to Donation and Transplantation of Donation After Circulatory Determination of Death Donors

Not-for-Profit community hospitals' exempt status at issue in charity care controversy

Response to American College of Physician's statement on the ethics of transplant after normothermic regional perfusion

Psychosocial, Legal, Ethical, and Cultural Aspects of Organ Donation and Transplantation

Analysis and Countermeasures of Sign Defect to Blood Transfusion Therapy of Informed Consent

Does It Matter How We Die? Ethical and Legal Issues Raised by Combining Euthanasia and Organ Transplantation

Biospecimen research and the law

Squaring the Circle. Brain death and organ transplantation

Correctional health care and Australian prisoners as recipients of kidney transplants: Legal and ethical issues

Examining Injustices: Transfusion Medicine and Race

Rationing expensive lifesaving medical treatments

Public health and the politics of school immunization requirements

Bloodless Medicine in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation